AbbVie (ABBV) CEO Michael received 82,439 shares
Insider transactions reported
Robert A. Michael (Chief Executive Officer at AbbVie Inc., ABBV) reported that they received 82,439 shares on Feb 18, 2026. After these transactions the filing shows 215,260 shares held directly.
- Reporting person
- Michael Robert A.
- Role
- CHIEF EXECUTIVE OFFICER
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Feb 18, 2026 | Grant or award (A) | Common Stock, $0.01 par value1, 2, 3, ... | +82,439 | - | - | 215,260 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Feb 18, 2026 | Grant or award (A) | Option (Right to Buy)On 81,251 Common Stock5 | +81,251 | - | - | 81,251 direct |
Holdings before and after
- Common Stock, $0.01 par value: 132,821 to 215,260 direct
- Option (Right to Buy): 0 to 81,251 direct
Footnotes from the filing
- 1. Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
- 2. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
- 5. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,084 on February 18, 2027, 27,084 on February 18, 2028, and 27,083 on February 18, 2029.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Michael report in this ABBV Form 4?
Robert A. Michael (Chief Executive Officer at AbbVie Inc., ABBV) reported that they received 82,439 shares on Feb 18, 2026. After these transactions the filing shows 215,260 shares held directly.
How many ABBV shares does Michael hold after this filing?
The filing shows 215,260 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for ABBV
Across the 26 sessions after earlier ABBV headlines, the stock closed higher 13 times and lower 13 times, with a median move of 1.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ABBV | SPY |
|---|---|---|---|
| Feb 20, 2026 | Barclays initiated coverage on AbbVie with a new price targetand 1 other headline that session | +0.2% | +0.7% |
| Feb 19, 2026 | AbbVie Declares Quarterly Dividend | -1.9% | -0.3% |
| Feb 4, 2026 | AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results | -3.8% | -0.5% |
| Feb 3, 2026 | Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Programand 1 other headline that session | +0.0% | -0.8% |
| Jan 28, 2026 | Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine | -2.3% | -0.0% |
| Jan 13, 2026 | AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans | +0.3% | -0.2% |
Earlier insider filings at ABBV
- Jan 5, 2026SEC Form 4 filed by Director Quaggin Susan E
- Jan 5, 2026SEC Form 4 filed by Director Alpern Robert J
- Jan 5, 2026SEC Form 4 filed by Director Rapp Edward J
- Oct 2, 2025SEC Form 4 filed by Director Quaggin Susan E
- Oct 2, 2025SEC Form 4 filed by Director Alpern Robert J
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2012
Follow ABBV and get a push notification the moment its next story breaks.